News for Apellis Pharmaceuticals, Inc. (APLS)

Baird analyst Colleen Kusy has maintained an "Outperform" rating on Apellis Pharmaceuticals (APLS) while raising the price target from $47.00 to $50.00 USD. Thi

Baird analyst Colleen Kusy has adjusted the price target for Apellis Pharmaceuticals (APLS), raising it from $47 to $50, while maintaining an Outperform rating.

On July 16, 2025, Tazeen Ahmad, an analyst at B of A Securities, maintained a neutral rating for Apellis Pharmaceuticals (APLS). This steady rating comes amidst

BofA has adjusted its price target for Apellis (APLS), increasing it from $23 to $24, while maintaining a Neutral rating on the stock. The change reflects the l

Apellis Pharmaceuticals (APLS) to present five abstracts on SYFOVRE® at the ASRS meeting. New data showcases SYFOVRE's ability to slow geographic atrop

Summary Apellis Pharmaceuticals Inc (APLS) announced on July 15, 2025, that five abstracts featuring their product SYFOVRE® (pegcetacoplan injection) have been

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On July 1, analyst Judah Frommer from Morgan Stanley raised the firm’s price target on Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) to $26.00 from $25.00 while maintaining a Hold rating on the stock. Frommer attributed the rating to […]

On June 24, Jared Holz, Mizuho's healthcare strategist, appeared on CNBC's 'Fast Money' to talk about competition in the obesity drug space.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is among the best growth stocks to invest in for the next 5 years. The General Counsel of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), David O. Watson, sold 5,000 shares of common stock for $18.77, higher than the current trading price of $17.62. This transaction, worth $93,850, although it follows a challenging period, […]

Morgan Stanley has maintained its 'Equal-Weight' rating for Apellis Pharmaceuticals (APLS) while raising the price target from $25.00 to $26.00. The updated pri

Apellis to receive $275 million upfront and up to $25 million in milestone payments upon EMA approval in C3G and IC-MPGNNon-dilutive financing further strengthens Apellis’ balance sheet Apellis retains full U.S. commercialization rights for systemic pegcetacoplanTransaction underscores shared confidence in the meaningful growth potential in rare kidney diseases WALTHAM, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced a capped royalty purchase agreement with Sobi® under which Apellis will receive up to $300 million in exchange for 90% of Apellis’ future ex-U.S. royalties for Aspaveli® (systemic pegcetacoplan). Under the companies’ 2020 collaboration agreement, Apellis is eligible for tiered royalties on ex-U.S. sales of Aspaveli ranging from high teens to high twenties. Apellis retains exclusive commercialization rights for systemic pegcetacoplan in the United States, where the product is marketed as EMPAVELI®.

July is observed as Sarcoma Awareness Month. Sarcoma is a rare type of cancer that affects muscles, fat, nerves, and other connective tissues. As we get ready to welcome July, it's also time to track the important FDA decisions lined up for the month.

Before making any decision, whether big or small, we instinctively weigh its long-term impact, and this is particularly true in the case of stocks.

Apellis Pharmaceuticals' latest phase 3 study shows promising results for Empaveli, reducing proteinuria by 68%. Analysts project significant upside pot

Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Apellis Pharmaceuticals (APLS) has announced encouraging outcomes from the Phase 3 VALIANT study concerning the drug EMPAVELI, aimed at treating C3 glomerulopat

**media[647749,647750]**

Apellis Pharmaceuticals (APLS) to present at the Goldman Sachs 46th Annual Global Healthcare Conference on June 11, 2025. The presentation will be avail

Summary Apellis Pharmaceuticals Inc (APLS), a global biopharmaceutical company known for pioneering complement medicine, announced on June 4, 2025, that it will